Bioanalysis is a term commonly used to describe the quantitative measurement of a drug or its metabolites in biological fluids. The determination of drug concentration in biological fluids provides data on the time course of drug action (PK) in animals and humans, which is an essential component of the drug discovery and development process.
Creative Bioarray develops and performs rapid, sensitive and robust bioanalytical methods for the extraction and quantitation of drugs and metabolites in biological fluids and tissues to support preclinical research. We provide cost-effective design and implementation of in vivo pharmacokinetic studies in various animal species and quick turnaround of results. Our bioanalytical capabilities serve every stage of your molecular development.
LC/MS/MS assays are mainly used for the analysis of small molecule drugs and metabolites in biological fluids. Creative Bioarray has developed and validated a range of methods and utilized these methods for preclinical pharmacology and toxicology studies.
Enzyme-linked immunosorbent assay (ELISA) determines and quantifies the proteins by attaching antibody to an enzyme that catalyze a chemiluminescent or colorimetric substrate. Scientists at Creative Bioarray utilize ELISA to determine the presence and concentration of the analytes in a sample.
Flow cytometry is powerful and versatile in investigating many aspects of cell biology during drug discovery and development. Creative Bioarray’s experiences include sorting of cells, enumeration of rare cellular subsets, as well as phenotypic and functional analysis of these subsets.
Creative Bioarray has the ability to develop a variety of cell-based testing assay for membrane integrity and ATP measurements, DNA replication, proliferation markers and antigen recognition. Our services in this domain include cell viability, cell proliferation, cell apoptosis, cell cycle and cellular phosphorylation assays.
At Creative Bioarray, we utilize in vitro and in vivo ADME studies to evaluate the dosage regimen, administration routes, and safety in different types of species. A series of models have been developed by our analysts to meet the requirements of your project.
To detect and characterize the level of immunogenicity, our scientists evaluate the anti-drug antibody (ADA) response of biopharmaceutical products using a multi-tiered approach including ADA prescreening, confirmatory assays, and anti-drug activity titers.
Our expertise in analyzing various analytes in multiplex and singleplex formats allows us to provide comprehensive biomarker testing services. These services include the method development and assay validation for novel biomarkers, development of tissue and fluid-based biomarkers, as well as assessment of GLP and GCP biomarker.
Scientists at Creative Bioarray conduct a series of cytotoxicity testing to control the quality of assay development and drug testing. An entire range of dosage of a compound is analyzed to determine the toxicity of the drug on living organisms.
At Creative Bioarray, we understand the pivotal significance of bioanalytical assays in efficacy and safety evaluation of the drug compound. Whether your focus is on small molecules, protein biotherapeutics, vaccines, or gene therapy, Creative Bioarray offers a full range of bioanalytical solutions to support all of drug development from discovery to clinical development.